Sandoz Group AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 20K
- Market Cap
- $19B
- Website
- http://www.sandoz.com
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fasted Conditions
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 50
- Registration Number
- NCT00857428
Bioavailability of Oxymorphone Hydrochloride 40 mg Extended Release Tablets Under Fed Conditions
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2017-03-29
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 32
- Registration Number
- NCT00857142
Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2008-07-09
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 114
- Registration Number
- NCT00711958
- Locations
- 🇷🇴
Oncologic Institute, Cluj-Napoca, Romania
🇩🇪Gemeinschaftspraxis mit Schwerpunkt Hämatologie und Internistische Onkologie, Bad Soden, Germany
🇩🇪Klinikum Nürnberg, 5. Medizinische Klinik Haus 12, Zimmer Nr. 13, Nürnberg, Germany
Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 337
- Registration Number
- NCT00701714
- Locations
- 🇦🇹
Diakonissen KH Salzburg, Salzburg, Austria
🇦🇹LKH Steyr, Steyr, Austria
🇦🇹Krankenanstalt der Stadt Wien, Wien, Austria
Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients
- Conditions
- Interventions
- First Posted Date
- 2008-04-25
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 478
- Registration Number
- NCT00666835
- Locations
- 🇦🇹
Allgemeines Krankenhaus der Barmherzigen Brüder Graz, Graz, Austria
🇦🇹Dialyseinstitut Graz GmbH, Graz, Austria
🇦🇹Universitätsklinik Innsbruck, Klinische Abteilung für Nephrologie, Innsbruck, Austria
Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.
- Conditions
- Interventions
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 1695
- Registration Number
- NCT00632125
- Locations
- 🇺🇦
Ternopilska Oblasna Klinichna Likarnia, Viddilennia Nefrologii ta Gemodializu, Ternopil, Ukraine
🇦🇹Landeskrankenhaus Feldkirch, Feldkirch, Austria
🇦🇹Universitätsklinik für Innere Medizin III, Wien, Austria
Safety and Efficacy of Omnitrope® (rhGH) in Short Children Born Small for Gestational Age (SGA)
- First Posted Date
- 2007-10-02
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 278
- Registration Number
- NCT00537914
- Locations
- 🇷🇴
Sandoz Investigational Site, Iaşi, Romania
A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002006
- Locations
- 🇺🇸
Natl Cancer Institute, Bethesda, Maryland, United States
A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002258
- Locations
- 🇺🇸
New England Deaconess Hosp, Boston, Massachusetts, United States
A Phase I/II Trial to Assess the Safety and Tolerance of Escalating Doses of a Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Retinitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Sandoz
- Registration Number
- NCT00002016
- Locations
- 🇺🇸
Harvard (Massachusetts Gen Hosp), Boston, Massachusetts, United States
🇺🇸Univ TX Galveston Med Branch, Galveston, Texas, United States